ResMed - RMD Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RMD shares.
View RMD analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued twelve-month price targets for ResMed's stock. Their RMD share price forecasts range from $250.00 to $280.00. On average, they expect the company's share price to reach $266.40 in the next twelve months. This suggests a possible upside of 23.8% from the stock's current price.
View analysts price targets for RMD or view top-rated stocks among Wall Street analysts.

ResMed's stock was trading at $260.48 at the beginning of the year. Since then, RMD shares have decreased by 17.4% and is now trading at $215.10.
View the best growth stocks for 2022 here.

ResMed saw a decline in short interest in August. As of August 15th, there was short interest totaling 1,320,000 shares, a decline of 28.3% from the July 31st total of 1,840,000 shares. Based on an average daily trading volume, of 560,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.9% of the company's shares are short sold.
View ResMed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our RMD earnings forecast.

ResMed Inc. (NYSE:RMD) released its quarterly earnings results on Thursday, August, 11th. The medical equipment provider reported $1.49 earnings per share for the quarter, topping analysts' consensus estimates of $1.48 by $0.01. The medical equipment provider had revenue of $914.74 million for the quarter, compared to analyst estimates of $912.53 million. ResMed had a trailing twelve-month return on equity of 26.56% and a net margin of 21.78%. The company's revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.35 EPS.
Read the conference call transcript.

ResMed announced a quarterly dividend on Friday, August 12th. Stockholders of record on Thursday, August 18th will be given a dividend of $0.44 per share on Thursday, September 22nd. This represents a $1.76 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date is Wednesday, August 17th. This is an increase from the stock's previous quarterly dividend of $0.42.
Read our dividend analysis for RMD.

ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.82%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 33.15%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 23.47% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (5.14%), State Street Corp (4.39%), WCM Investment Management LLC (4.39%), Northern Trust Corp (1.39%), Legal & General Group Plc (0.79%) and JPMorgan Chase & Co. (0.76%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends.

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMD stock can currently be purchased for approximately $215.10.

ResMed (NYSE:RMD) has a market capitalization of $31.50 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.31 on an earnings per share basis.

The company employs 8,160 workers across the globe.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.